NCT05062928 (REBOASIM) is a NA clinical trial of Virtual coach in Hemorrhage, sponsored by University of Florida.

Who is sponsoring NCT05062928?

NCT05062928 is sponsored by University of Florida.

What drugs are being tested in NCT05062928?

Interventions in NCT05062928: Virtual coach.

What condition does NCT05062928 study?

NCT05062928 studies Hemorrhage, Simulation Training.

Is NCT05062928 still recruiting?

NCT05062928 is currently completed. Last updated 20 November 2025.

Last reviewed 2025-11-20 · How we verify

NCT05062928: REBOASIM

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Mixed-reality REBOA Simulator With Virtual Coaching

Completed NA Last updated 20 November 2025

What this trial tests

NA trial testing Virtual coach in Hemorrhage in 14 participants. Completed in 11 November 2022.

Timeline

10 February 2022

Primary endpoint
11 April 2022

11 November 2022

Quick facts

Lead sponsor	University of Florida
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	other
Enrollment	14
Start date	10 February 2022
Primary completion	11 April 2022
Estimated completion	11 November 2022
Sites	1 location across United States

Drugs / interventions tested

Virtual coach

Conditions studied

Hemorrhage — all drugs for Hemorrhage →
Simulation Training — all drugs for Simulation Training →

Sponsor

University of Florida

Who can join

18 and older, any sex, with Hemorrhage or Simulation Training. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Resuscitative Endovascular Balloon Occlusion of the Aorta (REBOA) is a life-saving emergency procedure that is highly suited for simulation-based training. This study aims to assess the validity of our REBOA simulator with virtual coach (or live quantitative feedback) for mastery learning. The hypotheses are: H0: Virtual coach is non-inferior in REBOA training to an average human instructor. H1: Virtual coach is inferior in REBOA training to an average human instructor. We expect to learn whether the virtual coach is non-inferior to an average human instructor for US-guided REBOA training. Additionally, we expect to find which determinants affect success rate most and to assess the needs for the current simulator system's future software development.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

REBOA: A novel life-saving tool for non-compressible traumatic hemorrhage.
Hu W, Tian X, Li X, Liu F. · · 2024 · cited 1× · PMID 39101488 · DOI 10.1097/cm9.0000000000003243

Verify or expand the search:

Other trials of Virtual coach

Trials testing the same drug.

NCT06136468 — Humanoid-Technology Driven Health Enhancing Physical Activity · NA · completed

Other recruiting trials for Hemorrhage

Currently open trials in the same condition.

NCT07311343 — Oral Hygiene and Prophylactic Antibiotics to Prevent Intracerebral Hemorrhage Associated Pneumonia · Phase 4 · recruiting
NCT07105904 — Biological and Clinical Relevance of Quantra Viscoelastic Hemostatic Assay in Hemorrhagic Cardiac Surgery · active not recruiting
NCT06979466 — Q Therapeutic System for Chronic Stroke Recovery · NA · recruiting
NCT06664775 — A Study to Compare the Efficacy and Safety of TachoSil and Surgicel Original as an Adjunct to Control Mild to Moderate S · Phase 3 · recruiting
NCT06304714 — Effects of Bothrops Spp. Snake Envenomation on Willebrand Factor Activity in Martinique and French Guiana · recruiting

Other University of Florida trials

Trials by the same sponsor.

NCT03429413 — Maximizing HPV Vaccination: Real-time Reminders, Guidance, and Recommendations - Part 4: Feasibility Trial · NA · not yet recruiting
NCT06127550 — taVNS for Letter Learning in Dyslexia · NA · suspended
NCT07507214 — Optimized, Neuroplasticity-Enhanced-Depression (ONE-D) Transcranial Magnetic Stimulation (TMS) Treatment for Female Athl · Phase 2, PHASE3 · not yet recruiting
NCT07492316 — RNA-lipid Particle (RNA-LP) Vaccines for Recurrent/Progressive Medulloblastoma (MB) · Phase 1 · not yet recruiting
NCT06670794 — Using Ecological Momentary Data to Inform a Web Intervention for Romantic Partners Concerned About Their Loved Ones' Dri · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05062928 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of Florida
Last refreshed: 20 November 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05062928.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing